- FUJIFILM Diosynth Biotechnologies and TG Therapeutics enter a multi-year manufacturing agreement for BRIUMVI production.
- The partnership will leverage FUJIFILM Diosynth’s new facility in North Carolina, set to be operational in 2025, to expand supply for the FDA-approved MS therapy.
FUJIFILM Diosynth Biotechnologies has entered a multi-year agreement with TG Therapeutics to manufacture BRIUMVI (ublitiximab-xiiy), a U.S. FDA-approved treatment for relapsing multiple sclerosis (RMS). As part of the agreement, FUJIFILM Diosynth will provide secondary manufacturing from its upcoming biopharmaceutical facility in Holly Springs, North Carolina, slated to be fully operational in 2025.
TG Therapeutics’ decision to partner with FUJIFILM Diosynth aims to support the expanding commercialization of BRIUMVI and to ensure a reliable supply for the U.S. market. Michael S. Weiss, chairman and CEO of TG Therapeutics, stated, “We are excited to partner with FUJIFILM Diosynth Biotechnologies as a secondary manufacturer of BRIUMVI here in the United States, and believe their expertise makes them an ideal partner for us.”
Lars Petersen, president and CEO of FUJIFILM Diosynth, emphasised the company’s growth, saying, “This commitment recognises the expertise, capacity, and capabilities that FUJIFILM Diosynth Biotechnologies provides with our fully integrated manufacturing network.” The North Carolina site forms part of FUJIFILM Diosynth’s wider expansion strategy across the U.S., Europe, and Japan to meet rising biotherapeutic demands.
Overview of outsourcing trends 
